2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Phosphomannose Isomerase (PMI)

Phosphomannose Isomerase (PMI)

Phosphomannose Isomerase (PMI)

Phosphomannose isomerase (PMI/MPI), phosphomannose mutase (PMM), and GDP-Man pyrophosphorylase (GMPP) are the three crucial enzymes involved in the biosynthesis of GDP-Man, which is required for cell wall mannan biosynthesis and protein glycosylation. UDP-glucose (UDP-Glc), UDP-GlcNAc, and GDP-Man are the three precursors required for cell wall biosynthesis. PMI catalyzes the conversion between fructose-6-phosphate (Fru6P) and mannose-6-phosphate (Man6P)[1]. This enzyme is present in mammals, bacteria, and fungi and plays an important role in cell wall synthesis, viability, and cell signaling. PMI deficiency is associated with congenital disorder of glycosylation. PMI inhibition combined with mannose supplementation might help normalize N-glycosylation and improve CDG-Ia pathology[2].

Phosphomannose Isomerase (PMI) Related Products (3):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-112945
    MLS0315771
    		Inhibitor 99.46%
    MLS0315771 is a potent and biologically active competitive phosphomannose isomerase (MPI) inhibitor, with an IC50 ~1 μM and a Ki of 1.4 μM.
    MLS0315771
  • HY-138802
    ML089
    		Inhibitor 99.86%
    ML089 is a potent, selective, and orally available phosphomannose isomerase (PMI) inhibitor with an IC50 of 1.3 µM. ML089 can be used for the research of congenital disorder of glycosylation Ia.
    ML089
  • HY-124890
    Thr101
    		Inhibitor 99.36%
    Thr101 is an inhibitor (IC50=2.9 μM) of phosphomannose isomerase (PMI).PMI can compete with phosphomannose mutase 2 (PMM2) for the binding site of Man-6-P and convert mannose-6-phosphate (Man-6-P) into fructose-6-phosphate (Fru-6-P) .Thr101 only specifically inhibits PMI and not PMM2. Thr101 can be used for research of congenital disorder of glycosylation type Ia (CDG-Ia).
    Thr101